(Q53240738)

12 May 2018

title

The acute promyelocytic leukaemia success story: curing leukaemia through targeted therapies. (English)

1 reference

12 May 2018

1 reference

K L Rice

1

1 reference

12 May 2018

H de Thé

series ordinal

2

1 reference

12 May 2018

language of work or name

English

0 references

publication date

1 July 2014

1 reference

12 May 2018

Journal of Internal Medicine

published in

1 reference

12 May 2018

volume

276

1 reference

12 May 2018

issue

1

1 reference

12 May 2018

page(s)

61-70

1 reference

12 May 2018

Retinoic acid and arsenic trioxide for acute promyelocytic leukemia

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome 17

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

The PML-RARα fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

Fusion of retinoic acid receptor alpha to NuMA, the nuclear mitotic apparatus protein, by a variant translocation in acute promyelocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

The PRKAR1A gene is fused to RARA in a new variant acute promyelocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

The seventh pathogenic fusion gene FIP1L1-RARA was isolated from a t(4;17)-positive acute promyelocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

BCOR as a novel fusion partner of retinoic acid receptor alpha in a t(X;17)(p11;q12) variant of acute promyelocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

OBFC2A/RARA: a novel fusion gene in variant acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

Sequence and characterization of a coactivator for the steroid hormone receptor superfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

The nuclear hormone receptor coactivator SRC-1 is a specific target of p300.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

The corepressor CTBP2 is a coactivator of retinoic acid receptor/retinoid X receptor in retinoic acid signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

Oligomerization of RAR and AML1 transcription factors as a novel mechanism of oncogenic activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

Reconstructing a disease: What essential features of the retinoic acid receptor fusion oncoproteins generate acute promyelocytic leukemia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

Forced homo-oligomerization of RARalpha leads to transformation of primary hematopoietic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

Forced retinoic acid receptor alpha homodimers prime mice for APL-like leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

PML-RARA-RXR oligomers mediate retinoid and rexinoid/cAMP cross-talk in acute promyelocytic leukemia cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

PML-RARalpha/RXR Alters the Epigenetic Landscape in Acute Promyelocytic Leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

In vivo activation of cAMP signaling induces growth arrest and differentiation in acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

Rexinoid-triggered differentiation and tumor-selective apoptosis of acute myeloid leukemia by protein kinase A-mediated desubordination of retinoid X receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

Molecular signature of retinoic acid treatment in acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

Multimeric complexes of the PML-retinoic acid receptor alpha fusion protein in acute promyelocytic leukemia cells and interference with retinoid and peroxisome-proliferator signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

Expression of NPM-RARalpha fusion gene in hematopoietic cells confers sensitivity to troglitazone-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

Dimerization: a versatile switch for oncogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

The methyl-CpG binding protein MBD1 is required for PML-RARalpha function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

MBD3, a component of the NuRD complex, facilitates chromatin alteration and deposition of epigenetic marks.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

Role of the polycomb repressive complex 2 in acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

A sumoylation site in PML/RARA is essential for leukemic transformation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

Ubiquitinated or sumoylated retinoic acid receptor alpha determines its characteristic and interacting model with retinoid X receptor alpha in gastric and breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

The cell biology of disease: Acute promyelocytic leukemia, arsenic, and PML bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

PML is critical for ND10 formation and recruits the PML-interacting protein daxx to this nuclear structure when modified by SUMO-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

Human Daxx regulates Fas-induced apoptosis from nuclear PML oncogenic domains (PODs).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

Regulation of E2Fs and senescence by PML nuclear bodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

Regulation of p53 activity in nuclear bodies by a specific PML isoform

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

The function of PML in p53-dependent apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

Atmospheric carbon dioxide concentrations over the past 60 million years

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

PML is a direct p53 target that modulates p53 effector functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

Impairment of p53 acetylation, stability and function by an oncogenic transcription factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

PML colocalizes with and stabilizes the DNA damage response protein TopBP1

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations in acute promyelocytic leukemia: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

Acute promyelocytic leukemias share cooperative mutations with other myeloid-leukemia subgroups.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

Sequencing a mouse acute promyelocytic leukemia genome reveals genetic events relevant for disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

Role of PML in cell growth and the retinoic acid pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

Pml represses tumour progression through inhibition of mTOR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

Loss of the tumor suppressor PML in human cancers of multiple histologic origins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

Proto-oncogene PML controls genes devoted to MHC class I antigen presentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

Adaptive immunity cooperates with liposomal all-trans-retinoic acid (ATRA) to facilitate long-term molecular remissions in mice with acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

How acute promyelocytic leukaemia revived arsenic

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor alpha (RARalpha) and oncogenic RARalpha fusion proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

Autophagy contributes to therapy-induced degradation of the PML/RARA oncoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

Acute promyelocytic leukaemia: novel insights into the mechanisms of cure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

Single-agent liposomal all-trans retinoic acid can cure some patients with untreated acute promyelocytic leukemia: an update of The University of Texas M. D. Anderson Cancer Center Series.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

Uncoupling RARA transcriptional activation and degradation clarifies the bases for APL response to therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

Valproic acid induces differentiation and transient tumor regression, but spares leukemia-initiating activity in mouse models of APL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

RARalpha-PLZF overcomes PLZF-mediated repression of CRABPI, contributing to retinoid resistance in t(11;17) acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

Curing APL through PML/RARA degradation by As2O3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

PML induces a novel caspase-independent death process

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

Therapy-induced selective loss of leukemia-initiating activity in murine adult T cell leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

Interferon-α (IFN-α) suppresses HTLV-1 gene expression and cell cycling, while IFN-α combined with zidovudine induces p53 signaling and apoptosis in HTLV-1-infected cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

Dual Role of p53 in Innate Antiviral Immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

SUMOylation of p53 mediates interferon activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

Effective targeting of chronic myeloid leukemia initiating activity with the combination of arsenic trioxide and interferon alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12208

21 January 2018

Identifiers

DOI

10.1111/JOIM.12208

1 reference

12 May 2018

1 reference

12 May 2018